论文部分内容阅读
本文综合六省一市24个医院协作进行酶免疫法鼻咽癌诊断试剂盒临床考核的结果,共检测3329份各种血清标本的EB病毒 VCA-IgA抗体,其中1656例鼻咽癌患者,抗体的阳性率为92.51％,抗体几何平均滴度为 42.10,分析了三个医院的临床期、颈淋巴结转移和原发灶各期与抗体滴度的关系,表明本试剂对鼻咽癌有较高的特异性,敏感性强、可重现性高、操作简便、不需特殊的设备,检测血清的 VCA-IgA抗体可作为鼻咽癌早期诊断和鉴别诊断的血清学方法、并可作为高发地区人群普查的工具。
In this paper, 24 hospitals in six provinces and one city of the collaborative enzyme immunoassay nasopharyngeal cancer diagnostic kit results, a total of 3329 serum samples of a total of detection of Epstein-Barr virus VCA-IgA antibody, of which 1656 cases of nasopharyngeal carcinoma patients, antibodies The positive rate of antibody was 92.51%. The geometric mean titer of antibody was 42.10. The clinical, cervical lymph node metastasis and primary antibody titers in three hospitals were analyzed. The results showed that this reagent had a higher level of NPC Specificity, sensitivity, reproducibility, easy to operate, no special equipment, serum VCA-IgA antibody can be used as early diagnosis and differential diagnosis of nasopharyngeal carcinoma serological methods, and can be used as a high incidence area Crowd Census Tool.